Brief Communications

Postsynaptic GABA_B Receptors Enhance Extrasynaptic GABA_A Receptor Function in Dentate Gyrus Granule Cells

Wucheng Tao,² Matthew H. Higgs,^{1,2} William J. Spain,^{1,2,3} and Christopher B. Ransom^{1,3}

¹Epilepsy Center of Excellence, Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, and ²Department of Physiology and Biophysics and ³Department of Neurology, University of Washington, Seattle, Washington 98195

Ambient GABA in the brain tonically activates extrasynaptic GABA_A receptors, and activity-dependent changes in ambient GABA concentration can also activate GABA_B receptors. To investigate an interaction between postsynaptic GABA_B and GABA_A receptors, we recorded GABA_A currents elicited by exogenous GABA (10 μ M) from dentate gyrus granule cells (DGGCs) in adult rat hippocampal slices. The GABA_B receptor agonist baclofen (20 μ M) enhanced GABA_A currents. This enhancement was blocked by the GABA_B receptor antagonist CGP 55845 and intracellular solutions containing the GTP analog GDP- β -s, indicating that baclofen was acting on postsynaptic GABA_B receptors. Modulation of GABA_A currents by postsynaptic GABA_B receptors was not observed in CA1 pyramidal cells or layer 2/3 cortical pyramidal neurons. Baclofen reduced the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) but did not alter sIPSC amplitude or kinetics. Thus, GABA_A receptors activated at synapses were not modulated by postsynaptic GABA_B receptors. In contrast, tonic GABA currents and currents activated by the GABA_A receptor δ subunit-selective agonist THIP (10 μ M) were potentiated by baclofen. Our data indicate that postsynaptic GABA_B receptors enhance the function of extrasynaptic GABA_A receptors, including δ subunit-containing receptors that mediate tonic inhibition in DGGCs. The modulation of GABA_A receptor function by postsynaptic GABA_B receptors is a newly identified mechanism that will influence the inhibitory tone of DGGCs when GABA_B and GABA_A receptors are both activated.

Introduction

The inhibitory neurotransmitter γ -aminobutyric acid (GABA) activates both ionotropic GABAA receptors and metabotropic GABA_B receptors. GABA_A receptors are Cl⁻ ion channels that produce electrical signals when activated. GABAA receptors respond transiently to GABA released from synaptic vesicles and, in many areas of the brain including the hippocampus, high-affinity GABA_A receptors at extrasynaptic sites are activated tonically by ambient GABA (Farrant and Nusser, 2005; Glykys and Mody, 2007). Activation of presynaptic and postsynaptic GABA_B receptors stimulates intracellular G-protein signaling cascades that activate K + channels, inhibit voltage-gated Ca 2+ channels, and regulate cyclic AMP (cAMP) and protein kinase A (PKA) (Padgett and Slesinger, 2010). Because postsynaptic GABA_B receptors are located at extrasynaptic sites away from GABA release sites, their activation is limited by GABA uptake and requires patterns of presynaptic activity that lead to GABA spillover and elevations of ambient GABA (Scanziani, 2000; Kulik et al., 2003). Under conditions of increased ambient GABA, such as occur with ischemia, epileptic seizures, or drugs that increase GABA concentration, coactivation of GABA_A receptors and postsynaptic GABA_B receptors will occur (Scanziani et al., 1991; During and Spencer, 1993; Wu et al., 2003; Allen et al., 2004).

In dentate gyrus granule cells (DGGCs), electron microscopy with immunogold labeling has identified GABA_B receptors at perisynaptic sites on dendritic and somatic membranes (Kulik et al., 2003), a distribution pattern that has remarkable overlap with the distribution of extrasynaptic GABA_A receptor subunits that mediate tonic inhibition in DGGCs (i.e., δ subunits) (Wei et al., 2003). The proximity of postsynaptic GABA_B receptors to extrasynaptic GABA_A receptors on DGGCs suggests that GABA_A receptors will be exposed to intracellular signaling pathways activated by GABA_B receptors. This potential interaction has likely been overlooked, because studies of GABA_B receptors are routinely done in the presence of GABA_B receptor antagonists.

We investigated the interaction between GABA_B receptors and GABA_A receptors in DGGCs. Our data show that activation of postsynaptic GABA_B receptors enhances GABA_A currents caused by exogenous GABA. This newly identified interaction was not present in CA1 pyramidal neurons or layer 2/3 cortical pyramidal neurons. In DGGCs, tonic GABA currents and currents mediated by δ subunit-containing receptors were also modulated by GABA_B receptor activation. Our results indicate that extrasynaptic GABA_A receptor function will be enhanced when postsynaptic GABA_B receptors are activated, increasing the inhibitory tone of DGGCs.

Received Oct. 12, 2012; revised Nov. 27, 2012; accepted Dec. 24, 2012.

Author contributions: W.T., M.H., W.J.S., and C.B.R. designed research; W.T. and C.B.R. performed research; W.T. and C.B.R. analyzed data; W.T., M.H., W.J.S., and C.B.R. wrote the paper.

This work was supported by a Veterans Affairs (VA) Merit Review Award (W.J.S.), a VA Career Development Award (C.B.R.), and the VA Epilepsy Centers of Excellence (C.B.R., W.J.S., M.H.H.). The authors appreciate the expert technical assistance of Sue Usher and discussions with Professor Bertil Hille during the course of experiments.

Correspondence should be addressed to Dr. Christopher B. Ransom, Department of Neurology, University of Washington, Epilepsy Center of Excellence, VA Puget Sound, 1600 South Columbian Way, Seattle, WA 98108. E-mail: chr5@uw.edu.

DOI:10.1523/JNEUROSCI.4829-12.2013

Copyright © 2013 the authors 0270-6474/13/333738-06\$15.00/0




Figure 1. GABA_B receptor activation enhanced GABA_A currents in DGGCs, but not CA1 pyramidal neurons or cortical layer 2/3 pyramidal neurons. *A*, GABA_A currents evoked by focal application of GABA (10 μ M) before and during bath application of baclofen (20 μ M) (left panel). Middle panel shows time course of current change during baclofen application for this cell. Horizontal bars indicate the period of drug application here and in subsequent figures. Right panel shows mean current amplitudes under control conditions (con) and in the presence of baclofen. *B*, GABA currents in the presence of the GABA_B antagonist CGP 55845 (10 μ M) before and during baclofen application (left), time course of current change for this cell (middle), and mean current under control conditions (con) and in the presence of baclofen (right panel). CGP prevented baclofen effects on GABA_A currents. *C*, GABA currents before and after application of CGP alone (left), time course for this cell (middle), and mean current amplitude (right). *D*, Normalized currents (baclofen/control) for experiments on DGGCs, CA1 pyramidal cells, and layer 2/3 pyramidal cells. Error bars represent SEM; *p < 0.05, **p < 0.05, **p < 0.01, n.s., nonsignificant.

Materials and Methods

Brain slice preparation. Brain slices were prepared from 4–6 week old Sprague Dawley rats of both sexes. Rats were anesthetized with 4% isoflurane, decapitated, and the brain dissected free. Transverse hippocampal slices (300 $\mu \rm m$) were prepared. These slices contained portions of temporal cortex that were used for experiments on cortical neurons. Slices were cut and stored in a solution containing (in mm): 125 NaCl, 3 KCl, 26 NaHCO $_3$, 1.2 NaH $_2$ PO $_4$, 0.5 CaCl $_2$, 4 MgCl $_2$, 20 dextrose, and 1 kynurenic acid. Slices were cut in ice-cold solution and stored at room temperature. Solutions were continuously gassed with 95% O $_2$ /5% CO $_2$. Slices were allowed to recover for 1 h before recording. All animal use protocols were approved by the local Institutional Animal Care and Use Committee.

Electrophysiology. Membrane currents were recorded using whole-cell patch clamp techniques. Neurons were visualized with an Axioskop 2 upright microscope with fixed stage (Carl Zeiss). Recordings were made using an Axopatch 200B amplifier, a Digidata 1200 series A-D converter, and pClamp 9 software (Molecular Devices). Data were acquired at 2 kHz and low-pass filtered at 1 kHz. Series resistance was compensated by 50-70% online. If series resistance exceeded 20 M Ω or changed by >20%, the experiment was discarded. Focal application of GABA or bicuculline was made by pressure ejection (Picospritzer II, General Valve) from a patch pipette containing (in mm): 150 NaCl, 3 KCl, 2 CaCl₂, 2 MgCl₂, 10 dextrose, and 10 HEPES with pH adjusted to 7.4 with NaOH. The pressure ejection pipette was positioned \sim 20–30 μ m from the soma. The recording chamber was continuously superfused at \sim 2– 2.5 ml/min with a bath solution containing (in mm): 134 NaCl, 3 KCl, 1.4 NaH₂PO₄, 24 NaHCO₃, 10 dextrose, 2 MgCl₂, 2 CaCl₂, and 1 kynurenic acid (pH 7.35–7.4 when bubbled with 95% O₂/5% CO₂). Osmolarity was adjusted to 300–305 mOsm with $\rm H_2O.$ Patch pipettes were pulled from borosilicate glass with filament (Sutter Instrument). Pipettes had resistances of 3–4 $\rm M\Omega$ when filled with intracellular solution containing (in mm): 125 CsCl, 10 QX-314 chloride, 10 HEPES, and 1 EGTA (pH corrected to 7.25 with CsOH). Osmolarity was adjusted to 275–285 mOsm with $\rm H_2O$ as needed. Data acquisition was started 4–6 min after establishing a whole-cell recording. Experiments were performed at room temperature ($\sim\!23^{\circ}\rm C$). All chemicals were purchased from Sigma except SKF 89976a (Tocris-Cookson) and QX-314 (Alomone Labs). Baclofen was used at 20 $\mu\rm M$ (Dutar and Nicoll, 1988), and CGP55845 was used at 10 $\mu\rm M$ (Chen and Regehr, 2003).

Analysis. Data analysis was performed with Clampfit (pClamp 10) and Origin (v6.1, Microcal Software) software. Tonic currents were measured as the change in holding current caused by the GABA_A receptor antagonist bicuculline methiodide (40 μ M), based on Gaussian fits to all-points current amplitude histograms constructed from 2–10 s of data with a bin width of 1 pA. Fits were performed using a Levenberg–Marquardt algorithm in Clampfit, and the holding current was taken as the center of the Gaussian curve. IPSCs were analyzed using template matching event detection. Data are presented as mean \pm standard error of the mean (SEM), and all error bars represent SEM. Statistical analyses were performed using Microsoft Excel. A two-tailed, paired or homoscedastic Student's t test was used with a p value \leq 0.05 considered as significant.

Results

$GABA_B$ receptor activation enhanced $GABA_A$ receptor currents in a cell type-specific manner

To investigate an interaction between metabotropic GABA_B receptors and ionotropic GABA_A receptors, we made focal applica-

tions of GABA (10 μ M) to activate GABA_A currents in DGGCs ($V_{\rm m} = -60$ mV). Bath application of the GABA_B receptor agonist baclofen (20 µM) increased GABA-evoked currents by 83 ± 18% (control, -358 ± 143 pA vs baclofen, -577 ± 184 pA, n = 5, p < 0.01) (Fig. 1*A*). Currents in the presence of baclofen were inhibited by bicuculline (20 μ M) to a similar extent as under control conditions (control, 91 \pm 2% inhibition, baclofen, 95 \pm 1% inhibition, n = 3-4, p = 0.26), indicating that currents enhanced by baclofen were also mediated by GABAA receptors (data not shown). Modulation of GABA_A currents by baclofen was blocked by the GABA_B receptor antagonist CGP55845 (CGP, $10 \mu M$). In the presence of CGP, GABAA currents were -521 ± 120 pA at baseline and $-486 \pm$ 138 pA after application of baclofen (n =5, p = 0.38) (Fig. 1*B*). These data indicate that activation of GABA_B receptors augments GABAA receptor function in DG-GCs. CGP by itself reduced GABAA currents, demonstrating baseline activa-

tion of GABA_B receptors (and modulation of GABA_A receptors) during application of GABA. On average, CGP alone reduced GABA_A currents from -309 ± 87 pA to -187 ± 62 pA (n=5, p<0.05) (Fig. 1*C*).

We tested the effects of baclofen on GABA-evoked currents in hippocampal CA1 pyramidal cells and cortical layer 2/3 pyramidal cells. In contrast to results from DGGCs, baclofen did not modulate GABA_A currents in these other cell types (CA1: control -669 ± 173 pA vs baclofen -647 ± 163 pA, n=4, p=0.19; Layer 2/3: control -457 ± 103 pA vs baclofen -445 ± 96 pA, n=6, p=0.28) (Fig. 1D).

$\label{eq:modulation} \mbox{Modulation of GABA}_{\mbox{\scriptsize A}} \mbox{ current required postsynaptic } \\ \mbox{G-protein activation}$

Bath-applied baclofen activates both presynaptic and postsynaptic GABA_B receptors, raising the possibility of an indirect action (e.g., via modulation of GABA release). Because GABA_B receptors are G-protein coupled, transduction of receptor activation requires guanine nucleotide exchange. This process involves dissociation of GDP from inactive G proteins and binding of GTP. Thus, postsynaptic GABA_B receptor signaling can be prevented by intracellular GDP-β-S, a nonhydrolyzable GDP analog (Harayama et al., 1998; Lin and Dun, 1998). We recorded GABAA currents from DGGCs with intracellular solutions containing GDP- β -S (0.5 mm) and no GTP (Fig. 2A). Intracellular GDP- β -S prevented baclofen-induced potentiation of GABA_A currents (control, $-615 \pm 141 \text{ pA}$ vs baclofen, $-532 \pm 118 \text{ pA}$, n = 5, p = 0.12) (Fig. 2A). These results indicate that baclofen modulates GABA_A currents via postsynaptic GABA_B receptors and a G-protein signaling pathway.

Modulation of $GABA_A$ current was independent of synaptic vesicle release

Although changes in GABA release were not predicted to affect responses to exogenous GABA, we wished to exclude a contribution of vesicular GABA release to the effects of baclofen. To address this issue, we inhibited vesicular release of GABA by




Figure 2. Modulation of GABA_A currents by baclofen required postsynaptic G-protein activation and was independent of presynaptic vesicle release. **A**, GABA_A currents recorded with intracellular GDP- β -S to inhibit postsynaptic G proteins (left), time course of current change for this cell (middle), and mean current under control conditions (con) and in the presence of baclofen (right panel). Intracellular GDP- β -S blocked the effect of baclofen. **B**, Currents recorded from a DGGC pretreated with concanamy-cin A to inhibit vesicular GABA release (left). Baclofen increased GABA_A currents after ConA treatment (middle, current time course; right, mean current). *p < 0.05, ***p < 0.01.

pretreating slices with the H $^+$ -ATPase inhibitor concanamycin A (ConA, 0.5 μ M, 2 h). ConA treatment reduced the frequency of spontaneous IPSCs (sIPSCs) by 75% (n=9,p<0.05) (data not shown). However, ConA treatment did not affect the baclofeninduced potentiation of GABA_A currents (control, -437 ± 157 pA vs baclofen, -974 ± 167 pA, n=5,p<0.01) (Fig. 2B).

Baclofen potentiated tonic $GABA_A$ receptor currents, but not synaptic $GABA_A$ receptor currents

The data presented above show that postsynaptic GABA_B receptors can potentiate GABA_A currents elicited by exogenous GABA. Distinct types of GABA_A receptors with unique subunit compositions are transiently activated at synapses by vesicular GABA release or tonically activated by ambient GABA at extrasynaptic sites (Farrant and Nusser, 2005). To determine whether extrasynaptic GABA_A receptors were subject to modulation by postsynaptic GABA_B receptors, we measured tonic GABA_A current as the change in holding current caused by focal application of bicuculline (40 µm). Similar to its effect on exogenous GABA currents, baclofen potentiated tonic currents (control, -7.5 ± 1 pA vs baclofen, -15.2 ± 0.1 pA, n = 5, p < 0.01) (Fig. 3A, B). Tonic currents were unaffected by baclofen in the presence of CGP $(CGP, -5.5 \pm 1.2 \text{ pA vs baclofen/CGP}, -4.8 \pm 0.9, p = 0.44, n =$ 5) (Fig. 3C). In contrast to GABA-evoked currents, CGP alone did not affect tonic currents (control, -13.6 ± 3.0 pA vs CGP, -15.3 ± 3.4 , n = 4, p = 0.17) (Fig. 3C). This indicates that GABA_B modulation of tonic currents is not basally active and requires periods of increased ambient GABA (such as periodic application of exogenous GABA, i.e., Fig. 1C). Following inhibition of GABA uptake by SKF 89976a (SKF, 30 μM) to increase ambient GABA and tonic current, blocking GABA_B receptors with CGP significantly reduced tonic current (from -86.8 ± 17.9 pA to -45.9 ± 9.6 pA, n = 5, p < 0.01) (Fig. 3 D, E). These data indicate that GABA_B receptors modulate GABA_A receptors that mediate tonic currents.

Tonic currents in DGGCs are primarily mediated by δ subunit-containing GABA_A receptors (Glykys et al., 2008). To confirm that baclofen potentiates currents produced by δ




Figure 3. Postsynaptic GABA_B receptors increased tonic GABA_A currents. *A*, Tonic currents under baseline conditions (left) and during baclofen application (right). The histograms and Gaussian fits used to measure holding current before and during focal application of bicuculline (bic, 40 μm) are shown to the right of each trace, and each tonic current amplitude is indicated. *B*, Mean tonic current under control conditions and in the presence of baclofen. *C*, Tonic currents during application of baclofen (with CGP) or CGP alone normalized to control. *E*, Tonic currents in the presence of the GABA uptake inhibitor SKF 89976a (30 μm) before and during CGP application. *D*, Mean tonic currents in the presence of SKF or SKF + CGP. GABA_B antagonism by CGP reduced the large tonic current seen in the presence of SKF; **p < 0.01, n.s., nonsignificant.




Figure 4. GABA_B receptors increased currents evoked by the GABA_A receptor δ subunit-selective agonist THIP. **A**, Currents evoked by THIP (10 μ M) (left), the time course of current change for this cell (middle), and the mean THIP-induced currents under control conditions (con) and during baclofen application (right). **B**, THIP currents during application of baclofen (with CGP) or CGP alone normalized to control; **p < 0.01, n.s., nonsignificant.

subunit-containing GABA_A receptors, we used the δ subunit-selective agonist THIP (10 μ M). Baclofen increased currents evoked by THIP (control, -103 ± 19 pA vs baclofen, -167 ± 32 pA, n=5, p<0.05) (Fig. 4A). In the presence of CGP, baclofen had no effect on THIP-induced currents (CGP, -48 ± 13 pA vs baclofen/CGP, -46 ± 14 pA, p=0.56, n=5) (Fig. 4B). Similar to tonic currents, CGP alone did not affect THIP currents (control, -85.5 ± 18.9 pA vs CGP, -88.0 ± 19.3 pA, n=4, p=0.50) (Fig. 4B). These results demonstrate that δ subunit-containing GABA_B receptors are a target of postsynaptic GABA_B receptors.

Measurements of sIPSCs showed that baclofen reduced their frequency to $52 \pm 6\%$ of control values (n=5, p<0.05) but did not significantly affect sIPSC amplitude, 10-90% rise times, or decay times (n=5, p=0.94, 0.44, and 0.30, respectively) (data not shown). CGP alone did not affect sIPSC frequency, amplitude, or decay times (p=0.53, 0.52, and 0.33, respectively; n=4). These data indicate that GABA_B receptors reduce presynaptic release of GABA but do not alter the properties of GABA_A receptors activated at synapses (Otis and Mody, 1992).

Discussion

Our results show for the first time that postsynaptic GABA_B receptors can modulate GABA_A receptor function. Specifically, our data indicate that postsynaptic GABA_B receptors enhance the function of GABA_A receptors that produce tonic currents in DGGCs (including δ subunit-containing receptors). Because postsynaptic GABA_B receptors and the GABA_A receptors they modulate are located extrasynaptically (Kulik et al., 2003; Wei et al., 2003), both types of receptors will experience similar levels of ambient GABA. Coactivation of these receptors during periods of increased ambient GABA associated with intense neural activity may represent a feedback mechanism to increase inhibitory tone of DGGCs (Scanziani et al., 1991; During and Spencer, 1993; Scanziani, 2000).

Mechanism of ${\rm GABA_B}$ receptor modulation of ${\rm GABA_A}$ currents

Several lines of evidence indicate that GABA_A currents were modulated by postsynaptic GABA_B receptors. The use of exogenous

GABA to activate GABA_A currents would minimize effects of altered GABA release due to presynaptic GABA_B activation, and GABA_B effects were seen after inhibition of vesicular GABA release with ConA. Altered GABA uptake caused by presynaptic GABA_B receptor activation could potentially account for our observations. However, this is unlikely because GABA_B effects were seen in the presence of the GAT1 antagonist SKF. Additionally, currents produced by the nontransported GABA_A agonist THIP were potentiated by baclofen, indicating that GABA_B receptors enhance GABA_A currents independently of GABA uptake mechanisms (including GAT3). Finally, selectively inhibiting postsynaptic G proteins by including GDP- β -S in our pipette solutions blocked the effects of GABA_B receptor activation, confirming a postsynaptic site of action.

Our data show that tonic currents caused by ambient GABA are modulated by postsynaptic GABA_B receptors. Experiments using the δ subunit-selective agonist THIP (Mortensen et al., 2010; Meera et al., 2011) confirmed that receptors containing δ subunits were potentiated by GABA_B receptors. GABA_B receptor activation did not change sIPSC amplitude or kinetics but reduced sIPSC frequency, indicating that postsynaptic GABA_B receptors did not modulate GABA_A receptors activated at synapses. Because a large number of "synaptic-type" GABA_A receptors (i.e., γ subunit containing) are located away from synapses in extrasynaptic membranes (near postsynaptic GABA_B receptors) (Farrant and Nusser, 2005), our data do not exclude the possibility that GABA_B receptors modulate these types of GABA_A receptors in addition to δ subunit-containing receptors.

Signals mediated by postsynaptic GABA_B receptors are transduced by the G proteins G_i/G_o and $G_{\beta\gamma}$ (Padgett and Slesinger, 2010). A downstream effect of $G_{\beta\gamma}$ is K^+ channel activation; however, this is unlikely to have contributed significantly to our results because control currents and currents in the presence of baclofen were both inhibited >90% by GABA_A antagonists, and intracellular QX314 effectively blocks GABA_B-activated K⁺ channels (Nathan et al., 1990; Andrade, 1991). Activation of G_i/G_o inhibits adenylate cyclase, with subsequent reduction in cAMP levels and reduced activation of PKA. Our data show that inhibition of G-protein signaling prevented GABA_B receptor modulation of GABAA currents. The final effect on GABAA receptors is not known, but the possibilities include increased single channel conductance, open probability, or surface expression. Future studies using different experimental methods are required to distinguish between these possibilities.

Cell type specificity of the postsynaptic GABA_B–GABA_A interaction

In DGGCs, activation of GABA_B receptors substantially increased GABA_A currents by 83% on average. This strong modulation was absent in CA1 pyramidal neurons and cortical layer 2/3 pyramidal neurons. One salient difference between DGGCs and CA1 pyramidal cells is that tonic inhibition in CA1 pyramidal cells is mediated by α 5 subunit-containing GABA_A receptors, whereas δ subunit-containing receptors are dominant in DGGCs (Caraiscos et al., 2004; Glykys et al., 2008). In layer 2/3 pyramidal neurons there is little, if any, functional expression of δ subunits (although δ subunit mRNA is present) (Yamada et al., 2007). Thus, we speculate that signals produced by postsynaptic GABA_B receptors may preferentially affect δ subunits. Our results showed that baclofen did not affect sIPSC characteristics but potentiated tonic currents and THIP-evoked currents, consistent with a selective modulation of δ subunit-containing receptors by postsynaptic GABA_B receptors. However, other factors in addition to differences in GABA_A receptor subunit expression may also contribute to the cell type specificity of GABA_B receptor effects.

Functional implications

Tonic inhibition affects neuronal excitability and network behavior (Chadderton et al., 2004; Glykys and Mody, 2006; Pavlov et al., 2009; Duguid et al., 2012), thereby influencing many physiologic and pathophysiologic processes, including synaptic plasticity and epileptic seizures (Maguire et al., 2005; Martin et al., 2010). The effect of tonic inhibition is generally inhibitory, but in some cell types (i.e., thalamocortical cells) increasing tonic inhibition is maladaptive and contributes to pathologic patterns of neuronal firing (Cope et al., 2009). Our results add to the ways that tonic inhibition can be modulated, including GABA uptake and release by transporters, drugs that increase GABA concentrations, voltage-dependent modulation of extrasynaptic GABAA receptors, and neurosteroids (Overstreet and Westbrook, 2001; Nusser and Mody, 2002; Stell et al., 2003; Wu et al., 2003; Pavlov et al., 2009; Ransom et al., 2010). The enhancement of tonic inhibition by postsynaptic GABA_B receptors described here is predicted to reduce cellular excitability of DGGCs by shunting excitatory synaptic currents and raising action potential threshold (Stell et al., 2003; Holter et al., 2010; Arima-Yoshida et al., 2011; Gupta et al., 2012).

References

- Allen NJ, Rossi DJ, Attwell D (2004) Sequential release of GABA by exocytosis and reversed uptake leads to neuronal swelling in simulated ischemia of hippocampal slices. J Neurosci 24:3837–3849. CrossRef Medline
- Andrade R (1991) Blockade of neurotransmitter-activated K+ conductance by QX-314 in the rat hippocampus. Eur J Pharmacol 199:259–262. CrossRef Medline
- Arima-Yoshida F, Watabe AM, Manabe T (2011) The mechanisms of the strong inhibitory modulation of long-term potentiation in the rat dentate gyrus. Eur J Neurosci 33:1637–1646. CrossRef Medline
- Caraiscos VB, Elliott EM, You-Ten KE, Cheng VY, Belelli D, Newell JG, Jackson MF, Lambert JJ, Rosahl TW, Wafford KA, MacDonald JF, Orser BA (2004) Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A 101:3662–3667. CrossRef Medline
- Chadderton P, Margrie TW, Häusser M (2004) Integration of quanta in cerebellar granule cells during sensory processing. Nature 428:856–860. CrossRef Medline
- Chen C, Regehr WG (2003) Presynaptic modulation of the retinogeniculate synapse. J Neurosci 23:3130–3135. Medline
- Cope DW, Di Giovanni G, Fyson SJ, Orbán G, Errington AC, Lorincz ML, Gould TM, Carter DA, Crunelli V (2009) Enhanced tonic GABAA inhibition in typical absence epilepsy. Nat Med 15:1392–1398. CrossRef Medline
- Duguid I, Branco T, London M, Chadderton P, Häusser M (2012) Tonic inhibition enhances fidelity of sensory information transmission in the cerebellar cortex. J Neurosci 32:11132–11143. CrossRef Medline
- During MJ, Spencer DD (1993) Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341:1607–1610. CrossRef Medline
- Dutar P, Nicoll RA (1988) Pre- and postsynaptic GABAB receptors in the hippocampus have different pharmacological properties. Neuron 1:585–591. CrossRef Medline
- Farrant M, Nusser Z (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA_A receptors. Nat Rev Neurosci 6:215–229. CrossRef Medline
- Glykys J, Mody I (2006) Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA_A receptor α 5 subunit-deficient mice. J Neurophysiol 95:2796–2807. CrossRef Medline
- Glykys J, Mody I (2007) Activation of GABA_A receptors: views from outside the synaptic cleft. Neuron 56:763–770. CrossRef Medline
- Glykys J, Mann EO, Mody I (2008) Which GABAA receptor subunits are

- necessary for tonic inhibition in the hippocampus? J Neurosci 28:1421–1426. CrossRef Medline
- Gupta A, Elgammal FS, Proddutur A, Shah S, Santhakumar V (2012) Decrease in tonic inhibition contributes to increase in dentate semilunar granule cell excitability after brain injury. J Neurosci 32:2523–2537. CrossRef Medline
- Harayama N, Shibuya I, Tanaka K, Kabashima N, Ueta Y, Yamashita H (1998) Inhibition of N- and P/Q-type calcium channels by postsynaptic GABAB receptor activation in rat supraoptic neurones. J Physiol 509:371–383. CrossRef Medline
- Holter NI, Zylla MM, Zuber N, Bruehl C, Draguhn A (2010) Tonic GABAergic control of mouse dentate granule cells during postnatal development. Eur J Neurosci 32:1300–1309. CrossRef Medline
- Kulik A, Vida I, Luján R, Haas CA, Lopez-Bendito G, Shigemoto R, Frotscher M (2003) Subcellular localization of metabotropic GABA(B) receptor subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J Neurosci 23:11026–11035. Medline
- Lin HH, Dun NJ (1998) Post- and presynaptic GABA(B) receptor activation in neonatal rat rostral ventrolateral medulla neurons in vitro. Neuroscience 86:211–220. CrossRef Medline
- Maguire JL, Stell BM, Rafizadeh M, Mody I (2005) Ovarian cycle-linked changes in GABA_A receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 8:797–804. CrossRef Medline
- Martin LJ, Zurek AA, MacDonald JF, Roder JC, Jackson MF, Orser BA (2010) alpha5 GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J Neurosci 30:5269–5282. CrossRef Medline
- Meera P, Wallner M, Otis TS (2011) Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABAA receptors. J Neurophysiol 106:2057–2064. CrossRef Medline
- Mortensen M, Ebert B, Wafford K, Smart TG (2010) Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABAA receptors. J Physiol 588:1251–1268. CrossRef Medline
- Nathan T, Jensen MS, Lambert JDC (1990) The slow inhibitory postsynaptic potential in rat hippocampal CA1 neurones is blocked by intracellular injection of QX-314. Neurosci Lett 110:309–313. CrossRef Medline
- Nusser Z, Mody I (2002) Selective modulation of tonic and phasic inhibi-

- tions in dentate gyrus granule cells. J Neurophysiol 87:2624–2628. Medline
- Otis TS, Mody I (1992) Differential activation of GABAA and GABAB receptors by spontaneously released transmitter. J Neurophysiol 67: 227–235. Medline
- Overstreet LS, Westbrook GL (2001) Paradoxical reduction of synaptic inhibition by vigabatrin. J Neurophysiol 86:596–603. Medline
- Padgett CL, Slesinger PA (2010) GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol 58:123–147. CrossRef Medline
- Pavlov I, Savtchenko LP, Kullmann DM, Semyanov A, Walker MC (2009) Outwardly rectifying tonically active GABAA receptors in pyramidal cells modulate neuronal offset, not gain. J Neurosci 29:15341–15350. CrossRef Medline
- Ransom CB, Wu Y, Richerson GB (2010) Postdepolarization potentiation of GABAA receptors: a novel mechanism regulating tonic conductance in hippocampal neurons. J Neurosci 30:7672–7684. CrossRef Medline
- Scanziani M (2000) GABA spillover activates postsynaptic GABA(B) receptors to control rhythmic hippocampal activity. Neuron 25:673–681. CrossRef Medline
- Scanziani M, Gähwiler BH, Thompson SM (1991) Paroxysmal inhibitory potentials mediated by GABAB receptors in partially disinhibited rat hippocampal slice cultures. J Physiol 444:375–396. Medline
- Stell BM, Brickley SG, Tang CY, Farrant M, Mody I (2003) Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci U S A 100:14439–14444. CrossRef Medline
- Wei W, Zhang N, Peng Z, Houser CR, Mody I (2003) Perisynaptic localization of delta subunit-containing GABA(A) receptors and their activation by GABA spillover in the mouse dentate gyrus. J Neurosci 23:10650–10661. Medline
- Wu Y, Wang W, Richerson GB (2003) Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J Neurophysiol 89:2021–2034. Medline
- Yamada J, Furukawa T, Ueno S, Yamamoto S, Fukuda A (2007) Molecular basis for the GABAA receptor-mediated tonic inhibition in rat somatosensory cortex. Cereb Cortex 17:1782–1787. CrossRef Medline